<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03478449</url>
  </required_header>
  <id_info>
    <org_study_id>DJY001</org_study_id>
    <nct_id>NCT03478449</nct_id>
  </id_info>
  <brief_title>The Criteria for Lymph Node Sorting for Pathological Examination in Gastric Cancer</brief_title>
  <official_title>A Single Center Randomized Prospective Study on the Criteria for Lymph Node Sorting for Pathological Examination After Curative Surgery for Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is intending to provide the optimal procedures of lymph node sorting&#xD;
      for pathological examination after curative surgery for gastric cancer, which can&#xD;
      discriminate the differences of the status of lymph node metastasis, pTNM classification and&#xD;
      prognostic outcome of gastric cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">November 2, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Migration of pN stage in gastric cancer patients</measure>
    <time_frame>60 months</time_frame>
    <description>According to the overall survival of all included patients, we will evaluate the optimal lymph node sorting method to obtain the accurately pathological stage of lymph node metastatic counts (pN stage) for prediction the prognosis of patients after curative surgery for gastric cancer.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">276</enrollment>
  <condition>Lymph Node Metastases</condition>
  <condition>Gastric Cancer</condition>
  <condition>Exanimation</condition>
  <arm_group>
    <arm_group_label>Fine sorting lymph node group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Regional sorting lymph node group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>lymph node sorting for pathological examination</intervention_name>
    <description>In this study, intervention methods include two kinds of lymph node sorting for pathological examination in gastric cancer samples after curative surgery. One is the fine sorting lymph nodes, representing the lymph nodes should be sorted one by one from the tissues around the stomach, celiac axis, and the main brunches of celiac axis. The other is the group sorting lymph nodes, representing the lymph nodes should be simply sorted in the soft tissues around the stomach, celiac axis, and the main brunches of celiac axis.</description>
    <arm_group_label>Fine sorting lymph node group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) Physical conditions compliance with the requirements for curative gastrectomy&#xD;
&#xD;
          -  2) Consent to undergo the D2 lymphadenectomy&#xD;
&#xD;
          -  3) Comply with the protocol during the whole study period&#xD;
&#xD;
          -  4) No neoadjuvant therapy administration&#xD;
&#xD;
          -  5) Sign informed consent and permission of withdraw in the whole study period&#xD;
&#xD;
          -  6) Consent to provide the tissue specimens after surgery for this study&#xD;
&#xD;
          -  7) Pathological examination confirmation the adenocarcinoma of stomach before surgery&#xD;
&#xD;
          -  8) Estimation the overall survival after surgery no less than 6 months&#xD;
&#xD;
          -  9) No anesthesia or operation contraindication disease&#xD;
&#xD;
          -  10) cTanyNanyM0 stage demonstration by CT and endoscopic ultrasonography examinations&#xD;
&#xD;
          -  11) Negative cytological detection in operation&#xD;
&#xD;
          -  12) No seriously concomitance's diseases&#xD;
&#xD;
          -  13) Karnofsky Performance Scores (KPS) more than 60&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) Women during pregnant stage and breast-feed stage&#xD;
&#xD;
          -  2) Women of childbearing age without any contraceptive measures&#xD;
&#xD;
          -  3) Severe congestive heart failure, frequent arrhythmia, or myocardial infarction&#xD;
             within 12 months&#xD;
&#xD;
          -  4) Immunosuppressive therapists for organ transplantation&#xD;
&#xD;
          -  5) Seriously uncontrolled recurrent infection&#xD;
&#xD;
          -  6) other malignant tumors&#xD;
&#xD;
          -  7) No abilities of self-knowledge or mental disorders&#xD;
&#xD;
          -  8) Participating in other clinical trials&#xD;
&#xD;
          -  9) Siewert I and II esophagogastric junction tumors&#xD;
&#xD;
          -  10) Serious internal diseases obstruction surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cancer Hospital of Tianjin Medical University</name>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 10, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>November 10, 2020</last_update_submitted>
  <last_update_submitted_qc>November 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Lymphatic Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT03478449/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT03478449/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT03478449/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <pending_results>
    <submitted>March 30, 2021</submitted>
    <returned>April 26, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

